Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ssRNA-based immunomodulator CV8102

A 547 nucleotide (nt), noncoding, uncapped single-stranded RNA (ssRNA) containing several polyU-repeats complexed with a polymeric carrier formed by disulfide-crosslinked cationic peptides, with potential immunostimulating activity. Upon intratumoral injection, the ssRNA in CV8102 activates toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG I; RIG-I; DDX58). This stimulates a T-helper type 1 cell (Th1) response, the production of a variety of pro-inflammatory cytokines and chemokines, and activates a systemic cytotoxic-T-lymphocyte (CTL)-mediated immune response against the tumor cells when simultaneously exposed to tumor-associated antigens (TAAs). The cationic carrier peptides protect the ssRNA from RNase degradation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:RNA-based adjuvant CV8102
US brand name:RNAdjuvant
Code name:CV 8102
CV-8102
CV8102
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search